Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

@article{Singh2008InhaledAA,
  title={Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.},
  author={Sonal Singh and Yoon K Loke and Curt D. Furberg},
  journal={JAMA},
  year={2008},
  volume={300 12},
  pages={
          1439-50
        }
}
CONTEXT Inhaled anticholinergics (ipratropium bromide or tiotropium bromide) are widely used in patients with chronic obstructive pulmonary disease (COPD) but their effect on the risk of cardiovascular outcomes is unknown. OBJECTIVE To ascertain the cardiovascular risks of inhaled anticholinergics, including cardiovascular death, myocardial infarction (MI), and stroke. DATA SOURCES Systematic searches were conducted on March 19, 2008, of relevant articles in MEDLINE, the Cochrane Database… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 273 CITATIONS, ESTIMATED 44% COVERAGE

RECENT STUDIES OF THE RISKS AND BENEFITS OF INHALED THERAPY FOR COPD

VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Safety, tolerability and risk benefit analysis of tiotropium in COPD

VIEW 6 EXCERPTS
CITES RESULTS, BACKGROUND & METHODS
HIGHLY INFLUENCED

Cardiovascular safety of two bronchodilators' fixed-dose combination: indacaterol and glycopyrronium.

VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Treatment of stable chronic obstructive pulmonary disease: the GOLD guidelines.

VIEW 13 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Risks associated with tiotropium in chronic obstructive pulmonary disease: overview of the evidence to date

VIEW 5 EXCERPTS
CITES METHODS & BACKGROUND

Chronic obstructive pulmonary disease: a concise review.

VIEW 12 EXCERPTS
CITES RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2008
2020

CITATION STATISTICS

  • 18 Highly Influenced Citations

  • Averaged 14 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 46 REFERENCES

and Drug Administration

  • US Foo
  • Early communication about an ongoing safety review of tiotropium (marketed as Spiriva Handihaler). http://www .fda.gov/cder/drug/early_comm/tiotropium.htm. Accessed August 5,
  • 2008
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

Tiotropium improves FEV1 in patients with COPD irrespective of smoking status.

VIEW 12 EXCERPTS
HIGHLY INFLUENTIAL

Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD.

VIEW 11 EXCERPTS
HIGHLY INFLUENTIAL